Skip to main content

Saturn Medic

Clinical Subject Page

Systemic Hypertension

ICD-10

I10

Specialty

Cardiology

Onset

Acute & Chronic

Reviewed

June 2026
On This Page

Overview

Systemic hypertension (HTN) is a chronic condition characterized by persistently elevated systemic arterial blood pressure, increasing the risk of cardiovascular, cerebrovascular, renal, and vascular disease.

Etiology & Risk Factors

Etiology

  • Primary (Essential) hypertension (90–95%) : Idiopathic

  • Secondary hypertension

    • Chronic kidney disease

    • Renovascular disease

    • Primary hyperaldosteronism

    • Pheochromocytoma

    • Cushing syndrome

    • Obstructive sleep apnea

    • Thyroid disorders

    • Coarctation of the aorta

    • Medications (NSAIDs, steroids, oral contraceptives)

Risk Factors For Systemic Hypertension

      • Increasing age

      • Family history

      • Obesity

      • High-sodium diet

      • Physical inactivity

      • Smoking

      • Diabetes mellitus

      • Chronic kidney disease

      • Excess alcohol intake

      • Dyslipidemia

Pathophysiology

Systemic hypertension occurs when systemic vascular resistance (SVR) remains chronically elevated, causing persistently high arterial blood pressure.

Mechanism

  • Genetic and environmental factors activate the:
    • Sympathetic nervous system (SNS)
    • Renin–Angiotensin–Aldosterone System (RAAS)
  • This causes:
    • Vasoconstriction → ↑ systemic vascular resistance
    • Sodium and water retention → ↑ blood volume
    • ↑ Cardiac output (especially early in the disease)
  • Over time:
    • Blood vessels become thickened and less elastic (vascular remodeling)
    • Peripheral resistance increases further
    • The left ventricle works harder, leading to left ventricular hypertrophy (LVH)’

 

-Simple Flow

Risk factors → SNS & RAAS activation → Vasoconstriction + Na⁺/water retention → ↑ Blood volume + ↑ SVR → Persistent hypertension → Vascular remodeling + LV hypertrophy → Target-organ damage

Clinical Presentation

Symptoms

  • Often asymptomatic

  • Headache (usually severe HTN)

  • Dizziness

  • Blurred vision

  • Palpitations

  • Chest pain

  • Dyspnea

  • Fatigue

Signs

    • Elevated blood pressure

    • Hypertensive retinopathy

    • Left ventricular hypertrophy

    • S4 heart sound

    • Carotid or abdominal bruits (secondary causes)

Systemic Hypertension Overview
Systemic Hypertension Overview

History Taking

    • Duration of high blood pressure?
    • Home BP readings?
    • Current antihypertensive medications?
    • Medication adherence?
    • Chest pain or dyspnea?
    • Headache or visual changes?
    • Neurological symptoms?
    • Kidney disease?
    • Diabetes?
    • Alcohol, smoking, or illicit drug use?
    • Family history of hypertension or cardiovascular disease?

    Red Flags for Systemic Hypertension

    • BP ≥180/120 mmHg
    • Chest pain
    • Acute neurological deficits
    • Severe headache with vision changes
    • Pulmonary edema
    • Syncope

Grades of Systemic Hypertension

Hypertension · Grades / Classification

BP IS GRADED BY THE HIGHER OF EITHER SYSTOLIC OR DIASTOLIC VALUE Classification systems vary slightly (ESC/ESH vs ACC/AHA), both shown below. Diagnosis requires confirmation on repeated readings (clinic, home, or ambulatory BP monitoring) before labeling a patient hypertensive, except in hypertensive emergency.
ESC/ESH Classification (mmHg)
N
Optimal
SBP <120 and DBP <80
No treatment
N
Normal
SBP 120–129 and/or DBP 80–84
Lifestyle advice
HN
High-Normal
SBP 130–139 and/or DBP 85–89
Lifestyle ± monitor
G1
Grade 1 HTN
SBP 140–159 and/or DBP 90–99
Lifestyle + drug if risk
G2/3
Grade 2 / 3 HTN
Grade 2: SBP 160–179/DBP 100–109. Grade 3: SBP ≥180/DBP ≥110
Drug therapy now
Category ESC/ESH (SBP/DBP mmHg) ACC/AHA (SBP/DBP mmHg)
Optimal / Normal <120/80 <120/80
Elevated / Normal 120–129/80–84 120–129/<80
High-Normal 130–139/85–89 — (folded into Stage 1)
Grade 1 / Stage 1 HTN 140–159/90–99 130–139/80–89
Grade 2 / Stage 2 HTN 160–179/100–109 ≥140/≥90
Grade 3 HTN (Severe) ≥180/≥110 — (no separate grade 3 tier)
Isolated Systolic HTN SBP ≥140 with DBP <90 SBP ≥130 with DBP <80
Hypertensive Crisis SBP >180 and/or DBP >120 — emergency (end-organ damage) vs urgency (no end-organ damage)
Diagnostic Notes
Confirm before diagnosis — repeat clinic readings on ≥2 occasions, or use ABPM/HBPM to exclude white-coat/masked HTN
ABPM daytime average — ≥135/85 mmHg = hypertensive (lower threshold than clinic BP)
Home BP monitoring (HBPM) — average ≥135/85 mmHg = hypertensive
Classify by the higher value — e.g. 145/85 = Grade 1 (systolic-driven)
Use the same arm/position consistently; seated, after 5 min rest, no caffeine/smoking beforehand
Hypertensive Emergency vs Urgency
Hypertensive Emergency — severe BP rise with acute end-organ damage (encephalopathy, ACS, aortic dissection, AKI, papilledema) — needs IV therapy, controlled BP reduction
Hypertensive Urgency — severe BP rise without end-organ damage — oral therapy, gradual reduction over 24–48h
Avoid rapid correction — precipitous BP drops risk cerebral/coronary hypoperfusion
Target in emergency — reduce MAP by ≤25% in first hour, then gradually to normal over 24–48h (except aortic dissection/stroke — specific protocols)

Investigations

Laboratory

  • CBC

  • Electrolytes

  • Serum creatinine & eGFR

  • Urinalysis

  • Urine albumin/creatinine ratio

  • Fasting glucose or HbA1c

  • Lipid profile

  • TSH (if indicated)

ECG

  • Left ventricular hypertrophy

  • Ischemic changes

  • Arrhythmias

Imaging

  • Echocardiography (LVH, heart failure)

  • Renal ultrasound (if secondary cause suspected)

Additional Tests for Systemic Hypertension

      • Ambulatory Blood Pressure Monitoring (ABPM)

      • Home Blood Pressure Monitoring (HBPM)

      • Plasma aldosterone/renin ratio (if primary aldosteronism suspected)

      • Renal artery imaging (if renovascular disease suspected)

Diagnosis

Diagnosis of Systemic Hypertension is based on:

  • Repeated elevated office BP measurements
  • Confirmation with ABPM or HBPM when appropriate
  • Assessment for target-organ damage
  • Evaluation for secondary causes of Systemic Hypertension  in selected patients
Home / Home / Clinical Cases / Cardiovascular System Clinical Cases / Systemic Hypertension
Related Topics

Management (Drug of Choice)

Systemic Hypertension · Comorbidity-Based Drug of Choice

TAILOR ANTIHYPERTENSIVE CHOICE TO THE PATIENT'S COMORBID PROFILE First-line agents (ACEi/ARB, CCB, thiazide-like diuretic) form the backbone of therapy, but age, ethnicity, and comorbidities shift the preferred starting agent and key contraindications. Always individualise and check for drug interactions/pregnancy status.
HTN + Condition Drug of Choice Rationale / Notes
Diabetes Mellitus (any age, esp. <50 yrs) ACEi (or ARB) Renoprotective — reduces intraglomerular pressure and proteinuria, slows diabetic nephropathy progression.
Age <55 yrs, non-Black ACEi (or ARB) Renin-dependent hypertension more likely in younger patients — better response to RAAS blockade.
Age ≥55 yrs or Black patients (any age) CCB (e.g. amlodipine) Lower-renin physiology — better response to calcium channel blockade than RAAS agents per NICE/JNC guidance.
Chronic Kidney Disease (with proteinuria) ACEi (or ARB) Reduces proteinuria and slows CKD progression. Monitor K+ and creatinine after initiation.
Heart Failure with Reduced EF ACEi/ARB + Beta-blocker + MRA Guideline-directed medical therapy improves mortality; thiazides/loop diuretics for volume control as needed.
Post-Myocardial Infarction / CAD Beta-blocker + ACEi Beta-blockers reduce myocardial oxygen demand and arrhythmia risk; ACEi aids post-MI remodeling.
Angina (stable) Beta-blocker or CCB Both reduce myocardial oxygen demand; avoid non-dihydropyridine CCB with beta-blocker (bradycardia/AV block risk).
Atrial Fibrillation (rate control) Beta-blocker or non-DHP CCB Rate-controlling agents that also address BP; avoid non-DHP CCB if reduced EF.
Pregnancy Labetalol, Nifedipine, Methyldopa ACEi/ARB and direct renin inhibitors are contraindicated (teratogenic, fetal renal injury).
Gout / Hyperuricaemia CCB or ARB (losartan) Avoid thiazide diuretics — raise serum uric acid and can precipitate gout flares. Losartan has mild uricosuric effect.
Benign Prostatic Hyperplasia Alpha-blocker (e.g. doxazosin) Improves both BP and urinary symptoms; not first-line for BP alone, but useful add-on/dual-purpose agent.
Asthma / COPD CCB or ACEi/ARB Avoid non-selective beta-blockers (bronchospasm risk); cardioselective beta-blockers may be used cautiously if compelling indication.
Osteoporosis Thiazide diuretic Thiazides reduce urinary calcium excretion, modestly increasing bone mineral density — favourable secondary effect.
Migraine prophylaxis needed Beta-blocker (propranolol) Dual benefit — effective for both BP control and migraine prevention.
Essential Tremor Beta-blocker (propranolol) Non-selective beta-blockade reduces tremor amplitude in addition to BP control.
Hyperthyroidism / Thyrotoxicosis Beta-blocker Controls adrenergic symptoms (tachycardia, tremor) and BP simultaneously while definitive treatment is arranged.
Aortic Aneurysm / Marfan syndrome Beta-blocker Reduces aortic wall shear stress and rate of aneurysm growth/dissection risk.
Resistant Hypertension (on 3 drugs) Add Spironolactone 4th-line add-on of choice if K+ ≤4.5 mmol/L; alpha- or beta-blocker if K+ >4.5 mmol/L.
Key Contraindications to Remember
ACEi/ARB — pregnancy, bilateral renal artery stenosis, prior angioedema (ACEi)
Beta-blockers — severe asthma, high-grade AV block, decompensated HF, severe bradycardia
Thiazides — gout, severe hyponatraemia, symptomatic hypokalaemia
Non-DHP CCB (verapamil/diltiazem) — combination with beta-blocker, reduced EF heart failure
Spironolactone — hyperkalaemia, significant renal impairment
NICE/AB-CD Stepwise Approach (No Compelling Indication)
Step 1 — <55 yrs/non-Black: ACEi/ARB  |  ≥55 yrs or Black (any age): CCB
Step 2 — ACEi/ARB + CCB
Step 3 — ACEi/ARB + CCB + Thiazide-like diuretic
Step 4 (resistant) — add Spironolactone (K+ ≤4.5) or alpha-/beta-blocker (K+ >4.5)
Note — ACEi and ARB are never combined together due to hyperkalaemia/renal injury risk

Complications

      • Left ventricular hypertrophy
      • Heart failure
      • Coronary artery disease
      • Myocardial infarction
      • Stroke/TIA
      • Chronic kidney disease
      • Hypertensive retinopathy
      • Peripheral arterial disease
      • Aortic aneurysm/dissection

Prognosis

  • prognosis of Systemic Hypertension is Excellent with early diagnosis and BP control
  • Poorly controlled hypertension markedly increases cardiovascular and renal morbidity and mortality
  • Long-term treatment significantly reduces the risk of stroke, MI, heart failure, and death

Key Points / Clinical Pearls

  • Systemic Hypertension is persistently elevated systemic arterial blood pressure and is a major modifiable risk factor for cardiovascular and renal disease.
  • In the 2025 AHA/ACC guideline, hypertension is classified as Stage 1: 130–139 mmHg systolic or 80–89 mmHg diastolic and Stage 2: ≥140 mmHg systolic or ≥90 mmHg diastolic.
  • The 2024 ESC guideline continues to define hypertension as office BP ≥140/90 mmHg, while introducing elevated BP as 120–139/70–89 mmHg.
  • Most patients are asymptomatic, which is why hypertension is often called a “silent” disease.
  • Persistent hypertension increases the risk of stroke, coronary artery disease, heart failure, atrial fibrillation, chronic kidney disease, and cognitive decline.
  • Diagnosis should be based on properly measured and repeated blood-pressure readings, with home or ambulatory monitoring useful for confirming hypertension and identifying white-coat or masked hypertension.
  • Important risk factors include age, obesity, high sodium intake, physical inactivity, alcohol excess, family history, diabetes, and chronic kidney disease.
  • Lifestyle modification is fundamental: weight control, a heart-healthy/DASH-style diet, reduced sodium intake, appropriate potassium intake, regular physical activity, stress management, and limiting alcohol.
  • The 2025 AHA/ACC treatment goal is generally <130/80 mmHg for adults, with individualization for certain populations.
  • Iqbal AM, Jamal SF. National Center for Biotechnology Information (NIH). Essential Hypertension, StatPearls.
  • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71:e13-e115. PMID: 29133356.
  • Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the Management of Arterial Hypertension. J Hypertens. 2023;41:1874-2071. PMID: 37345492.
  • Hegde S, Ahmed I, Aeddula NR. National Center for Biotechnology Information (NIH). Secondary Hypertension, StatPearls.
  • Shams P, Tackling G, Borhade MB. National Center for Biotechnology Information (NIH). Hypertensive Heart Disease, StatPearls.